China trade mission invite

**THE** Australian Minister for Trade and Investment, Andrew Robb, is planning to lead an Australian Government business mission to China from 11-15 Apr 2016, and inviting interested parties to apply to join the mission, government sources have announced.

Australia Week in China (AWIC) 2016 will consist of around 80 trade, investment, education and tourism promotion events, delivered across multiple cities.

The events are designed to highlight commercial opportunities bolstered by the rise of an affluent middle class and the China Australia Free Trade Agreement.

Recent trade growth in complementary medicines, baby formula and other Australian labelled products (see article left) has highlighted the massive opportunities afforded by a growing economy with an increasing trend to consumer based growth, away from an export economy.

The program visits three cities with industry networking opportunities and site visits in Beijing, Hangzhou and Shanghai.

**New Zika threat**

**PRESENTLY** understood to be readily transmitted by the aedes aegyptae mosquito, the Zika virus has now also been detected in aedes albopictus, better known as the tiger or Asian tiger mosquito, a related species that has been responsible for transmission of two other arboviruses in Gabon, in the Republic of Congo on the west coast of Africa.

With “the global spread of this insect, these results present a new potential threat to human health around the world,” says the French research group Institut de recherche pour le développement.

The tiger mosquito has also been responsible for the spread of dengue and chikungunya viruses, the institut said.

A special pathology testing centre has been established in Townsville to rapidly test for Zika in humans, Australian authorities have said.
Pharmacist phone intervention

THE Medicines Advice Service Evaluation (MASE) conducted a trial of a pharmacist-led telephone-based intervention which may improve medication adherence, and has been published in BJM Quality and Safety. 677 patients prescribed at least one oral medication for type 2 diabetes were recruited to the study and randomised (340 intervention, 337 control). Intervention involved two telephone consultations with a pharmacist four to six weeks apart, plus a written summary and a reminder chart.

Analyses of dispensing data revealed the odds of being classified as adherent (≥90%) were 60% greater for the intervention group compared with the control group, however, patients who provided blood samples, glycaemic and lipid control did not differ.

Further work is needed to confirm a trend - CLICK HERE for the study.

St Vincent’s gives wrong drug dose

UP TO 70 cancer patients were given the wrong drug dose for a period of three years at Sydney’s St Vincent’s Hospital, according to reports by ABC News.

Medical oncologist Dr John Grygiel reportedly prescribed the same flat dosage of the drug carboplatin to patients with head and neck cancer without adjusting it according to their individual needs.

The dose is usually between 200 and 300mg but Dr Grygiel prescribed the same 100mg to all.

Hospital staff were reportedly aware of the error for at least six months but waited on the results of an external investigation released this week before contacting affected patients.

St Vincent’s Hospital has said the rate of “current disease and death was within expectations among this group of patients and the drug was a secondary treatment for all 70 patients.” Four of the 70 patients relapsed.

CEO confidence down

KINETICOS, in partnership with Ipsos Healthcare and Demy-Colton Life Science Advisors, have announced the Q4 2015 results of the Biopharma CEO Confidence Index, revealing a downward trend.

The measure is a forward-looking indicator designed to measure ceo confidence in the biopharma industry’s economy.

Those ceos with high confidence levels of being able to raise capital in the next 18 months declined from 53% in Q3 to 39% in Q4, while those who viewed the current deal landscape as good, declined from 82% to 61% in the same period.

CEOs very confident in their ability to deliver therapies in three to five years remained stable in Q4 at 91% compared to 86% in Q3 but only 33% of ceos believed transaction values were increasing in Q4, compared to 59% in Q3, the report said.

The data also showed that oncology (37%) and neurology (33%) remain the focus of licensing transactions - CLICK HERE for more.

Biosimilars course

THE US Food and Drug Administration (FDA) has released a free Continuing Education Course to help health care providers understand biosimilars.

Biological products that are “biosimilar” to, or “interchangeable” with, an already-approved FDA biological product, described as the “reference” product, with similar access and cost-saving motivations applying to Australia’s Therapeutic Goods Administration (TGA).

CLICK HERE for the FDA course and HERE for TGA information.

AbbVie Q1 dividend

GLOBAL, research-based biopharmaceutical company AbbVie has declared a quarterly dividend of US$0.57 per share, payable 16 May.

Since the company’s inception in 2013, AbbVie has increased its dividend by more than 42%, the company said through its NYSE announcement.

Z POS & Dispense Software

Manage your pharmacy seamlessly with an integrated solution that helps you manage your pharmacy with ease.

- Designed & developed by pharmacists
- Automatic real-time software & product updates including PBS updates (no manual end of month procedures)
- Automatic back-ups
- One centralised database
- Use your existing hardware*
- No up-front software licence fee and low monthly software service fee

Z POS & Dispense Support via Pharmacy Alliance

Pharmacy Alliance provides 24/7 help-desk support included in the monthly software service fee. Plus, receive an exclusive Pharmacy Alliance member only discount on monthly software service fees.

JOIN PHARMACY ALLIANCE TODAY TO ACCESS NEXT GENERATION PHARMACY SOFTWARE AND SUPPORT

For membership enquiries:
email: enquiries@pharmacyalliance.com.au call: 03 9860 3300
visit pharmacyalliance.com.au/z-software
linkedin.com/company/pharmacy-alliance

DO YOUR CLAIMING IN THE CLOUD

• Sort claims automatically
• Respond to audits instantly

**FREE for eRx Express pharmacies**

For Print

For eRx

www.pharmacydaily.com.au
Blackmores awards suppliers

BLACKMORES hosted its annual supplier conference at the company’s campus in Warriewood, Sydney, with suppliers of the year announced.

“At Blackmores we’ve been challenged to meet the growing demand because of our commitment to quality,” Blackmores chief operating officer Richard Henfrey said.

“We’re now producing more Blackmores products than ever before, and we couldn’t do this without our wonderful supply partners,” he continued.

This year Power Plastics scored the coveted Supplier of the Year award for “continuous improvement, proactvity and supply chain transparency”.

GC Reiber took out Blackmores Sustainability Award for supporting the company’s commitment to ingredient traceability, the community and the environment.

Pemara Labels Australia was awarded Outstanding Focus on Quality for maintaining Blackmores’ “unrivalled quality standards”.

Delivering Innovation was awarded to Lipa Pharmaceuticals, Setting the Pace given to Nutricorp International while Bega Cheese and Land Essence Group both took home Outstanding Achievement awards.

Henfrey said all those awarded deserved recognition for their hard work.

“Many are unsung heroes who are often not recognised for the role they play in supporting our business and ensuring we can deliver premium products to you,” Henfrey said.

Testosterone benefits

TESTOSTERONE treatment for men over 65 improves sexual function and can also aid mood and physical ability, according to a new study published in the New England Journal of Medicine.

The study monitored 790 men 65+ with low blood testosterone.

Results showed taking testosterone in the form of a gel applied to the skin raised levels to the middle of the normal range for men aged 19 to 40.

It also helped improve mood and depressive symptoms.

Win with Mute

This week Pharmacy Daily and Mute are giving away everyday two Mute starter packs.

Mute is a patented respiratory technology designed to gently stent open your nasal airway during sleep to increase the volume of air travelling through the nose, making nasal breathing much easier which may alleviate the incidence and severity of snoring.

Designed with the anatomy of the nose in mind, it sits comfortably in the nose and by gently dilating the airway, it may alleviate nasal congestion and obstruction, making it easier to breathe. Available in 3 sizes, (small, medium and large) freely adjust the dilation system to personalise the fit to each nostril.

To win, be the first two from VIC or TAS to send the correct answer to the question to comp@pharmacydaily.com.au

Generally, what size Mute do men typically use?

Congratulations to yesterday’s winners, Leah Hague from Symbion and Muthi Ahmed from Tenerrin Creek Pharmacy.
PARA'KITO™

**NATURALLY REDUCES YOUR MOSQUITO APPEAL**

Available in leading pharmacies, health & outdoor stores. View stockists at www.parakito.com or scan the code below.

Optica Code | Product Description | RRP Per Item (Incl. GST) | API | SYMBION | SIGMA
---|---|---|---|---|---
PARWCL | 12pc PARA’KITO™ Colour band display stand | $26.95 | 445304 | 128589 | 165704
PARWGF | 12pc PARA’KITO™ Graffic band display stand | $26.95 | 445320 | 128538 | 165688
PACDSP | 12pc PARA’KITO™ Clip display stand | $26.95 | 445460 | 128422 | 165639
PAKDSP | 12pc PARA’KITO™ Kids bands display stand | $26.95 | 7699 | 232262 | 200154
PARWCP | 12pc PARA’KITO™ Best sellers display stand | $26.95 | 10885 | 232270 | -
PARDSP | 12pc PARA’KITO™ Refill display stand | $16.95 | 445487 | 128406 | 165589

ORDER THROUGH YOUR PREFERRED WHOLESALER OR CONTACT OPTICA ON 1800 199 860